Gene Therapy for Retinal Degeneration

Cell

Volumn 173, Issue 1, 2018, Pages 5-

  Apte, Rajendra S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 CIS RETINAL; COMPLEMENTARY DNA; HYDROLASE; ISOMEROHYDROLASE; RETINOIC ACID; UNCLASSIFIED DRUG; VORETIGENE NEPARVOVEC; CIS TRANS ISOMERASE; RETINOID ISOMEROHYDROLASE;

CHROMATOPHORE; ENZYME ACTIVITY; GENE; GENE MUTATION; GENE THERAPY; GENETIC ASSOCIATION; GENETIC TRANSDUCTION; HUMAN; PHOTOTRANSDUCTION; PRIORITY JOURNAL; RETINA CONE; RETINA DEGENERATION; RETINA DYSTROPHY; RETINA ROD; RETINAL PIGMENT EPITHELIUM; RPE65 GENE; SHORT SURVEY; VISUAL IMPAIRMENT; ADENOVIRIDAE; DRUG THERAPY; ECONOMICS; GENE VECTOR; GENETICS; LEBER CONGENITAL AMAUROSIS; METABOLISM;

ADENOVIRIDAE; CIS-TRANS-ISOMERASES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LEBER CONGENITAL AMAUROSIS; RETINAL DEGENERATION;

EID: 85044132232     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.03.021     Document Type: Short Survey

References (9)

1. Allikmets, R., Leber congenital amaurosis: a genetic paradigm. Ophthalmic Genet. 25 (2004), 67–79.
2. Dias, M.F., Joo, K., Kemp, J.A., Fialho, S.L., da Silva Cunha, A. Jr., Woo, S.J., Kwon, Y.J., Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog. Retin. Eye Res., 2017, 10.1016/j.preteyeres.2017.10.004.
3. Gu, S.M., Thompson, D.A., Srikumari, C.R., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K.R., Rathmann, M., Kumaramanickavel, G., Denton, M.J., Gal, A., Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat. Genet. 17 (1997), 194–197.
4. Hamel, C.P., Tsilou, E., Pfeffer, B.A., Hooks, J.J., Detrick, B., Redmond, T.M., Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro. J. Biol. Chem. 268 (1993), 15751–15757.
5. Jin, M., Li, S., Moghrabi, W.N., Sun, H., Travis, G.H., Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell 122 (2005), 449–459.
6. Marlhens, F., Bareil, C., Griffoin, J.M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.Y., Harris, E., Redmond, T.M., Arnaud, B., et al. Mutations in RPE65 cause Leber's congenital amaurosis. Nat. Genet. 17 (1997), 139–141.
7. Russell, S., Bennett, J., Wellman, J.A., Chung, D.C., Yu, Z.F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390 (2017), 849–860.
8. Sohocki, M.M., Daiger, S.P., Bowne, S.J., Rodriquez, J.A., Northrup, H., Heckenlively, J.R., Birch, D.G., Mintz-Hittner, H., Ruiz, R.S., Lewis, R.A., et al. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum. Mutat. 17 (2001), 42–51.
9. Food and Drug Administration. 2017 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/ucm574396.htm.